Oculis Holding, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Serge Belanger from Needham maintained a Buy rating on the stock and has a $36.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Serge Belanger has given his Buy rating due to a combination of factors surrounding Oculis Holding’s strategic developments and market potential. The company is advancing its OCS-05 program following a favorable meeting with the FDA, which is a significant step forward in their neuro-ophthalmology initiatives. The positive outcomes from the phase 2 trial for OCS-05, which showed meaningful improvements in various clinical endpoints, underscore its potential as a groundbreaking treatment for conditions like AON and NAION.
These conditions currently lack approved treatments, presenting a substantial market opportunity with patient populations exceeding 30,000 in the U.S. alone. Given the high pricing typical for rare disease therapies, each condition could represent a multi-billion dollar market. The acceleration of phase 3 trials and the initiation of a registrational program further highlight the company’s commitment and potential for success, making Oculis Holding an attractive investment opportunity.
According to TipRanks, Belanger is a 4-star analyst with an average return of 6.8% and a 47.11% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, KalVista Pharmaceuticals, and MoonLake Immunotherapeutics.
In another report released today, Bank of America Securities also maintained a Buy rating on the stock with a $30.00 price target.